Deschatelets Pascal's Form 4 filing
Apellis Pharmaceuticals, Inc.APLS · filed Apr 9, 2024
- Accession no.
- 0001127602-24-012710
- Filed
- Apr 9, 2024
- Trade date
- Apr 8, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.74M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deschatelets PascalCIK 0001657720 | Officer (Chief Scientific Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 8, 2024 | Common Stock | MOption exerciseAcquired | +69,107 | $3.76 | +$259,842.32 | 1,185,090 | Direct | |
| Apr 8, 2024 | Common Stock | SSaleDisposed | −64,379 | $54.12F3 | −$3,484,191.48 | 1,120,711 | Direct | |
| Apr 8, 2024 | Common Stock | SSaleDisposed | −4,728 | $54.92F4 | −$259,661.76 | 1,115,983 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 8, 2024 | Common Stock | MOption exerciseDisposed | −69,107 | $0.00 | $0 | 37,280 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
This transaction was executed in multiple trades at prices ranging from $53.770 - $54.765. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $54.775 - $55.750. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.